Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Gross Profit: 2017-2024

Historic Gross Profit for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $434.4 million.

  • Protagonist Therapeutics' Gross Profit rose 0.79% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.6 million, marking a year-over-year decrease of 35.12%. This contributed to the annual value of $434.4 million for FY2024, which is 624.05% up from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' Gross Profit is $434.4 million, which was up 624.05% from $60.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Gross Profit registered a high of $434.4 million during FY2024, and its lowest value of $26.6 million during FY2022.
  • Moreover, its 3-year median value for Gross Profit was $60.0 million (2023), whereas its average is $173.7 million.
  • In the last 5 years, Protagonist Therapeutics' Gross Profit surged by 12,293.07% in 2020 and then fell by 4.44% in 2021.
  • Over the past 5 years, Protagonist Therapeutics' Gross Profit (Yearly) stood at $28.6 million in 2020, then fell by 4.44% to $27.4 million in 2021, then declined by 2.84% to $26.6 million in 2022, then spiked by 125.73% to $60.0 million in 2023, then surged by 624.05% to $434.4 million in 2024.